Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial
Launched by STANFORD UNIVERSITY · Dec 5, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Sequential, Multiple Assignment, Double Randomized Preference Migraine Behavioral Trial, is investigating different behavioral treatments for chronic migraine, a condition where people experience frequent headaches for at least a year. The goal is to find the best combinations of these treatments and see how participants' preferences for certain options might affect their experience during the trial.
To participate, individuals must be at least 18 years old and have a history of chronic migraine. Unfortunately, those with other types of headaches or who are under 18 years old cannot join. If you decide to participate, you can expect to try different treatment options and provide feedback on what works best for you. The trial is currently looking for volunteers, so it’s a great opportunity to contribute to research that could help improve migraine management for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • have chronic migraine for a minimum of 1-year
- • aged 18 years and older
- Exclusion Criteria:
- • secondary headache disorders
- • children younger than 18 years old
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Yohannes W Woldeamanuel, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported